Last reviewed 2026-05-15 · How we verify

Pandemic flu H5 HA mRNA SD2 vaccine

Sanofi · Phase 1 active Biologic Quality 0/100

Pandemic flu H5 HA mRNA SD2 vaccine is a Biologic drug developed by Sanofi. It is currently in Phase 1 development.

At a glance

Generic name	Pandemic flu H5 HA mRNA SD2 vaccine
Sponsor	Sanofi
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Pandemic flu H5 HA mRNA SD2 vaccine CI brief — competitive landscape report
Pandemic flu H5 HA mRNA SD2 vaccine updates RSS · CI watch RSS
Sanofi portfolio CI

Frequently asked questions about Pandemic flu H5 HA mRNA SD2 vaccine

What is Pandemic flu H5 HA mRNA SD2 vaccine?

Pandemic flu H5 HA mRNA SD2 vaccine is a Biologic drug developed by Sanofi.

Who makes Pandemic flu H5 HA mRNA SD2 vaccine?

Pandemic flu H5 HA mRNA SD2 vaccine is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

What development phase is Pandemic flu H5 HA mRNA SD2 vaccine in?

Pandemic flu H5 HA mRNA SD2 vaccine is in Phase 1.

Manufacturer: Sanofi — full pipeline
Compare: Pandemic flu H5 HA mRNA SD2 vaccine vs similar drugs
Pricing: Pandemic flu H5 HA mRNA SD2 vaccine cost, discount & access